Mesa Laboratories

Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Instrument segment designs, manufactures, and markets control instruments and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. The Biopharmaceutical Development segment develops and sells automated systems for protein analysis and peptide synthesis solutions. The Continuous Monitoring segment includes development of systems used to monitor various environmental parameters. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mesa Labs (MLAB) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $2.22 per share a year ago.

Mesa Labs (MLAB) Q4 Earnings and Revenues Miss Estimates

LAKEWOOD, Colo., May 25, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q23”) and fiscal year (“FY23”) ended March 31, 2023.

Mesa Labs Announces Unaudited Fourth Quarter and Full Fiscal Year 2023 Results

In Q3, Mesa Laboratories reported mixed results throughout the P&L with soft bottom-line fundamentals. FCF growth still lumpy with contraction in divisional growth.

Mesa Laboratories: Divisional Growth, Valuations Supportive Of Hold

Mesa Labs (MLAB) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Mesa Labs (MLAB) a Solid Growth Stock? 3 Reasons to Think "Yes"

Mesa Labs (MLAB) delivered earnings and revenue surprises of 11.90% and 5.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Tops Q3 Earnings Estimates

Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.

What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?

Here is how Mesa Labs (MLAB) and Cassava Sciences, Inc. (SAVA) have performed compared to their sector so far this year.

Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year?

LAKEWOOD, Colo., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023.

Mesa Labs Declares Quarterly Dividend

After Q2 results, EPS estimates soar 39% as revenues grow 24% on strong M&A strategies

Bull of the Day: Mesa Labs (MLAB)

LAKEWOOD, Colo., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2023 at approximately 8:00 A.M. Eastern time on Monday, February 6, 2023.

Mesa Laboratories, Inc. to Announce Third Quarter Results on February 6, 2023

Dynatronics

Shockwave Medical

The Zacks Medical - Instruments industry is growing on rising demand for digital health. SWAV, MLAB and DYNT are set to gain the most.

3 Medical Instruments Stocks to Buy as Inflation Clouds Prospects

Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Moving Higher for Mesa Labs (MLAB): Time to Buy?

Lakewood, Colorado, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, today announced the acquisition of substantially all of the assets (other than current assets) and certain liabilities related to Belyntic GmbH's (“Belyntic”) peptide purification business. The transaction price and near-term financial impact are not material to Mesa's ongoing operations.

Mesa Labs Acquires Belyntic's Peptide Purification Business

Appointment is a Key Step in Enhancing Mesa's Corporate Governance Appointment is a Key Step in Enhancing Mesa's Corporate Governance

Mesa Laboratories, Inc. Appoints Shiraz Ladiwala as Lead Independent Director

Mesa Labs (MLAB) delivered earnings and revenue surprises of 107.19% and 10.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Q2 Earnings and Revenues Top Estimates

Mesa Labs (MLAB) delivered earnings and revenue surprises of -40% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Q1 Earnings and Revenues Miss Estimates

Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mesa Labs (MLAB) to Report Q1 Results: Wall Street Expects Earnings Growth

LAKEWOOD, Colo., June 27, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its Board of Directors (the “Board”), effective June 23, 2022. Tony was previously the Executive Vice President and Chief Financial Officer of Corning, Incorporated and retired on May 2, 2022.

Mesa Laboratories Appoints Tony Tripeny to its Board of Directors

Mesa Labs (MLAB) delivered earnings and revenue surprises of 18.09% and 6.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Surpasses Q4 Earnings and Revenue Estimates

LAKEWOOD, Colo., May 31, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the fourth quarter (“4Q22”) and full year ended March 31, 2022 (“FY22”).

Mesa Labs Reports Fourth Quarter and Full Fiscal Year Results

Mesa Labs (MLAB) delivered earnings and revenue surprises of -19.05% and 13.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Q3 Earnings Miss Estimates

Mesa Labs (MLAB) Earnings Expected to Grow: Should You Buy?

23andMe

Medpace Holdings

These smaller healthcare companies all have 10x potential for investors.

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

Edwards Lifesciences

Sensus Healthcare

What History Shows Us About 2022 Market Returns

Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy

News for Mesa Laboratories Stock (MLAB)